AFSA is an all volunteer nonprofit organization dedicated to funding research that investigates the causes and treatments for fibromyalgia syndrome.

A 501(c)3 Nonprofit Charitable Organization.

Through donations, AFSA supports studies that seek out the causes and treatments for fibromyalgia (FM). This is an extremely painful, fatiguing, and often debilitating medical condition that affects 3-5 percent of the population. By stepping up research on FM, AFSA and its generous contributors are working together to make a substantial difference in the lives of millions.

AFSA is currently accepting research applications that focus on two key areas: (1) identifying the possible causes or markers of this disease and (2) evaluating new treatments. The deadline date is March 1, 2024.

A trial funded by AFSA showed that low-dose naltrexone (LDN) significantly relieved FM pain in one-third of patients. This is better than any of the FDA-approved drugs for the condition and the side effects are next to nil. Unlike most meds prescribed for FM that alter the way the neurons work, LDN mostly targets the immune cells in the nervous system.

Read more about the AFSA trial, how LDN works, and other studies related to this novel treatment approach to chronic pain. In addition, four FM treatment experts offer advice on: Giving LDN Your Best Shot.

A better understanding of what is going on in the brain, including the microglia, is essential for developing effective treatments for FM. What is causing the microglia activation and are there any markers in the blood that may signal a disruption of microglia function? Read about the most recent AFSA-funded study designed to shed light on these questions.